Formulation and Drug Delivery

Solving the challenge of better-stabilized temperature-sensitive biomolecules hinges on innovative formulation strategies.

Employing novel technologies and more patient-centric approaches can help to reduce the potential of formulation failure.

CordenPharma has partnered with Spain-based Certest to develop ionizable lipids for LNP formulations.

Collaboration is a key component to achieving long-term success with genetic medicines.

When considering manufacturing and the growth of drug formulation, it is evident that there has been change and many new advancements introduced to make processes more efficient.

According to a press release, the implications go to the extent that within the next 10 years, more than 50% of approved drugs will involve AI in their development and/or manufacturing.

Optibrium announced on Aug. 31, 2023 the acquisition of BioPharmics to further expand the 3D drug design and modelling offering and to focus on research and development and application science.

SBS-518 is a first-in-class dual sigma receptor (SR) antagonist/dopamine transporter (DAT) inhibitor in development for the treatment of stimulant use disorder (StUD).

Dr. Ulrike Lemke, Head of Sterile Fill Finish at Recipharm, sat down with Grant Playter, associate editor, to discuss drug delivery forms.

These models are useful in predicting whether an unknown substance of abuse can permeate the BBB to produce effects predicted by the Public Health Assessment via Structural Evaluation (PHASE) approach.

Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.

Advancements in therapeutic modalities are necessitating change in drug delivery to help negate some of the expense of development and manufacturing.

The members reviewed the measures to minimize the risk of serious side effects associated with Janus kinase (JAK) inhibitors used to treat several chronic inflammatory disorders.

The guidance discusses statistical approaches for BE comparisons and focuses on how to use these approaches both generally and in specific situations.

Opportunities and developments in particle engineering are providing developers with the tools to advance drug candidates successfully.

One company reaches beyond traditionally-conceived male contraceptives with Vasalgel, a reversible hydrogel injectable.

External expertise is beneficial in helping companies select the right tools at the right stages of development to ensure success.

There are many benefits of employing a reformulation strategy, but companies must also overcome a variety of challenges too.

Some of the greatest advancements in drug delivery are related to disposable delivery devices, vaccine adjuvants, and wearable pumps, according to Nicholas W. Warne of Pfizer.

It is possible to overcome some of the limitations of traditional dosage forms by employing alternative drug delivery formulation strategies.

Industry is adapting to the increasing complexity and poor solubility and bioavailability of molecules in the pipeline.

Biologics are forming a greater proportion of the development pipeline, but there are still some formulation difficulties to overcome to ensure clinical and commercial success.

Putting the patient at the forefront of drug development is essential, particularly to ensure medication compliance is optimized.

An early formulation strategy for tablets that is simple and scalable is recommended to ensure fewer downstream problems.

Technological advances are helping shape the dosage forms of the future.

Developers need to consider key challenges when approaching accelerated formulation strategies to ensure success.

Toxicology studies are an important and required aspect of drug development that are performed to ensure that drugs are deemed safe prior to patient administration and use in clinical trials.

Poor solubility remains a big issue for drug development and, as such, is driving innovation in approaches and use of novel technologies to help overcome the associated challenges.

Investing in formulation strategies earlier on in development will maximize the chance of success.

Alternative drug delivery approaches are promising, but due to their complexity, they need to be sufficiently justified.